Tg Therapeutics (TGTX) Deferred Taxes (2025 - 2026)

Tg Therapeutics (TGTX) posted quarterly Deferred Taxes of $3.9 million for Q1 2026, down 87.75% quarter-over-quarter from $31.6 million in Q4 2025.

Tg Therapeutics (TGTX) Deferred Taxes (2025 - 2026) Analysis & Trends

Tg Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $3.9 million for Q1 2026.

In Q1 2026, Deferred Taxes changed N/A year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $35.4 million (changed N/A YoY), while the FY2025 annual figure was -$335.1 million, changed N/A from the prior year.
Deferred Taxes for Q1 2026 stood at $3.9 million, down from $31.6 million in the prior quarter.
The five-year high for Deferred Taxes was $31.6 million in Q4 2025, with the low at $3.9 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-137,876.64
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.66 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Tg Therapeutics	7.46 Bn	6.78 Bn	199.14 Mn	708,000.00

Download Data